{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:23:45Z","timestamp":1791894225566,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001942","name":"European Coordinated Research on Long-term Challenges in Information and Communication Sciences & Technologies ERA-NET","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017337","name":"Fondation Imagine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jaci.2021.08.024","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T03:46:48Z","timestamp":1631850408000},"page":"1358-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-588X","authenticated-orcid":false,"given":"Claire","family":"Barbieux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Bonnet des Claustres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Fahrner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam C.","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Leturcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Nicaise-Roland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"B\u00e9ziat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bourrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E.","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Hovnanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.08.024_bib1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/75977","article-title":"Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome","volume":"25","author":"Chavanas","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2021.08.024_bib2","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/hmg\/ddg247","article-title":"LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome","volume":"12","author":"Bitoun","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2021.08.024_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.0022-202X.2004.23583.x","article-title":"LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum","volume":"124","author":"Ishida-Yamamoto","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1172\/JCI41440","article-title":"Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing","volume":"120","author":"Bonnart","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.024_bib5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.jid.5700284","article-title":"Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome","volume":"126","author":"Descargues","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib6","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1091\/mbc.e07-02-0124","article-title":"LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction","volume":"18","author":"Deraison","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jaci.2021.08.024_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1515\/BC.2005.134","article-title":"Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI)","volume":"386","author":"Schechter","year":"2005","journal-title":"Biol Chem"},{"key":"10.1016\/j.jaci.2021.08.024_bib8","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1038\/jid.2011.174","article-title":"Proteolytic activation cascade of the Netherton syndrome\u2013defective protein, LEKTI, in the epidermis: implications for skin homeostasis","volume":"131","author":"Fortugno","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1084\/jem.20082242","article-title":"Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome","volume":"206","author":"Briot","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.024_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/edm.11.85","article-title":"Netherton syndrome: new advances in the clinic, disease mechanism and treatment","volume":"7","author":"Hovnanian","year":"2012","journal-title":"Exp Rev Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00441-013-1558-1","article-title":"Netherton syndrome: skin inflammation and allergy by loss of protease inhibition","volume":"351","author":"Hovnanian","year":"2013","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jaci.2021.08.024_bib12","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1515\/hsz-2014-0137","article-title":"Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy","volume":"395","author":"Furio","year":"2014","journal-title":"Biol Chem"},{"key":"10.1016\/j.jaci.2021.08.024_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jaci.2009.06.009","article-title":"Com\u00e8l-Netherton syndrome\u2014defined as primary immunodeficiency","volume":"124","author":"Renner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1111\/all.14197","article-title":"Comel-Netherton syndrome: a local skin barrier defect in absence of an underlying systemic immunodeficiency","volume":"75","author":"Stuvel","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.08.024_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/DAD.0000000000000425","article-title":"Skin biopsy in Netherton syndrome: a histological review of a large series and new findings","volume":"38","author":"Leclerc-Mercier","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaci.2021.08.024_bib16","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaci.2016.07.019","article-title":"An IL-17\u2013dominant immune profile is shared across the major orphan forms of ichthyosis","volume":"139","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib17","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/jid.2013.517","article-title":"Intercellular skin barrier lipid composition and organization in Netherton syndrome patients","volume":"134","author":"van Smeden","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1194\/jlr.RA120000639","article-title":"Skin barrier lipid enzyme activity in Netherton patients is associated with protease activity and ceramide abnormalities","volume":"61","author":"Smeden","year":"2020","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jaci.2021.08.024_bib19","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/jid.2010.233","article-title":"Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model","volume":"130","author":"Briot","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib20","doi-asserted-by":"crossref","first-page":"32095","DOI":"10.1074\/jbc.M513138200","article-title":"Proteinase-activated receptors, targets for kallikrein signaling","volume":"281","author":"Oikonomopoulou","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2021.08.024_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.jid.5700965","article-title":"Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases","volume":"128","author":"Stefansson","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib22","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.celrep.2020.02.021","article-title":"Interplay of staphylococcal and host proteases promotes skin barrier disruption in Netherton syndrome","volume":"30","author":"Williams","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2021.08.024_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.chom.2017.10.006","article-title":"Staphylococcus aureus epicutaneous exposure drives skin inflammation via IL-36\u2013mediated T cell responses","volume":"22","author":"Liu","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jaci.2021.08.024_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaci.2018.03.021","article-title":"Ichthyosis molecular fingerprinting shows profound TH17 skewing and a unique barrier genomic signature","volume":"143","author":"Malik","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib25","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jid.2018.03.1523","article-title":"The major\u00a0orphan forms of ichthyosis are characterized by systemic T-cell activation and Th-17\/Tc-17\/Th-22\/Tc-22 polarization in blood","volume":"138","author":"Czarnowicki","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jamadermatol.2020.1019","article-title":"Secukinumab therapy for Netherton syndrome","volume":"156","author":"Luchsinger","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib27","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaad.2020.07.054","article-title":"Duality of Netherton syndrome manifestations and response to ixekizumab","volume":"84","author":"Barbieux","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jdcr.2020.04.025","article-title":"Successful use of secukinumab in Netherton syndrome","volume":"6","author":"Blanchard","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2021.08.024_bib29","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13\u2013dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng1493","article-title":"Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity","volume":"37","author":"Descargues","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2021.08.024_bib32","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20150204","article-title":"A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis","volume":"212","author":"Wu","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.024_bib33","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1016\/j.jid.2017.07.820","article-title":"IL-36\u03b3 induced by the TLR3-SLUG-VDR axis promotes wound healing via REG3A","volume":"137","author":"Jiang","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib34","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.7150\/ijms.20809","article-title":"IL-36\u03b3 inhibits differentiation and induces inflammation of keratinocyte via Wnt signaling pathway in psoriasis","volume":"14","author":"Wang","year":"2017","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jaci.2021.08.024_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-15892-7","article-title":"The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function","volume":"7","author":"Pfaff","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jaci.2021.08.024_bib36","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1034\/j.1600-0625.2002.110611.x","article-title":"Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin: NGAL is a marker for parakeratosis","volume":"11","author":"Mallbris","year":"2002","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/all.12051","article-title":"Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model","volume":"68","author":"Gschwandtner","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.08.024_bib38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1523-1747.1999.00566.x","article-title":"Expression of interferon-\u03b2 is associated with growth arrest of murine and human epidermal cells","volume":"112","author":"Bielenberg","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib39","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1084\/jem.20070157","article-title":"Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation","volume":"204","author":"Blumberg","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.024_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143334","article-title":"Epicutaneous Staphylococcus aureus induces IL-36 to enhance IgE production and ensuing allergic disease","volume":"131","author":"Patrick","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2021.08.024_bib41","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/jid.2011.234","article-title":"Inter-regulation of Th17 cytokines and the IL-36 cytokines in\u00a0vitro and in\u00a0vivo: implications in psoriasis pathogenesis","volume":"131","author":"Carrier","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib42","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1681\/ASN.2016080840","article-title":"IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23\/IL-17 axis in renal inflammation and fibrosis","volume":"28","author":"Chi","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jaci.2021.08.024_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36\u03b3 is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jaci.2021.08.024_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123390","article-title":"Disrupting the IL-36 and IL-23\/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis","volume":"4","author":"Germ\u00e1n","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.08.024_bib46","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900586","article-title":"Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice","volume":"3","author":"Hern\u00e1ndez-Santana","year":"2020","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.jaci.2021.08.024_bib47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2018.00080","article-title":"RNA-Seq analysis of IL-1B and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature","volume":"9","author":"Swindell","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib48","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.1073\/pnas.1801377115","article-title":"I\u03baB\u03b6 is a key transcriptional regulator of IL-36\u2013driven psoriasis-related gene expression in keratinocytes","volume":"115","author":"M\u00fcller","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2021.08.024_bib49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/jid.2014.532","article-title":"IL-36\u03b3 (IL-1F9) is a biomarker for psoriasis skin lesions","volume":"135","author":"D\u2019Erme","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u03b2-Defensin 2 is a responsive biomarker of IL-17A\u2013driven skin pathology in patients with psoriasis","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib51","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2018.00639","article-title":"Complement activation in inflammatory skin diseases","volume":"9","author":"Giang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib52","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2016.11.011","article-title":"Complement C3 exacerbates imiquimod-induced skin inflammation and psoriasiform dermatitis","volume":"137","author":"Giacomassi","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-\u03b1 production","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2021.08.024_bib54","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jid.2019.08.444","article-title":"IL-36 promotes systemic IFN-I responses in severe forms of psoriasis","volume":"140","author":"Catapano","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib55","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2021.08.024_bib56","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/jid.2012.149","article-title":"Type I IFNs at the interface between cutaneous immunity and epidermal remodeling","volume":"132","author":"Conrad","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib57","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3389\/fimmu.2019.01440","article-title":"Type 1 interferons potential initiating factors linking skin wounds with psoriasis pathogenesis","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib58","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jaci.2014.07.008","article-title":"IgE allergen component-based profiling and atopic manifestations in patients with Netherton syndrome","volume":"134","author":"Hannula-Jouppi","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib59","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/intimm\/dxl054","article-title":"CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model","volume":"18","author":"Chen","year":"2006","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2015.01.021","article-title":"TH9 cells are required for tissue mast cell accumulation during allergic inflammation","volume":"136","author":"Sehra","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib61","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.204.Supp.65.22","article-title":"The role of IL-9 secreting CD4+ T helper cells in promoting mast cell expansion in pulmonary models of inflammation","volume":"204","author":"Pajulas","year":"2020","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib62","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/mi.2017.21","article-title":"IL-36\u03b3 signaling controls the induced regulatory T cell\u2014TH9 cell balance via NF\u03baB activation and STAT transcription factors","volume":"10","author":"Harusato","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/icb.2010.53","article-title":"Regulation of human Th9 differentiation by type I interferons and IL-21","volume":"88","author":"Wong","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaci.2021.08.024_bib64","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/jid.2011.124","article-title":"Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin","volume":"131","author":"Fontao","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib65","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of Netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjd.18892","article-title":"Successful treatment of Netherton syndrome with ustekinumab in a 15-year-old girl","volume":"183","author":"Volc","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.08.024_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small molecule IL-36\u03b3 antagonist as a novel therapeutic approach for plaque psoriasis","volume":"9","author":"Todorovi\u0107","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2021.08.024_bib68","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.08.024_bib69","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.08.024_bib70","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921013981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921013981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:34:26Z","timestamp":1758792866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921013981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0091674921013981"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.024","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Netherton syndrome subtypes share IL-17\/IL-36 signature with distinct IFN-\u03b1 and allergic responses","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}